Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
AOI Pharma, Inc. Dana-Farber Cancer Institute |
---|---|
Information provided by: | AOI Pharma, Inc. |
ClinicalTrials.gov Identifier: | NCT00448721 |
This is a single-arm phase II trial of perifosine in renal cancer patients who have experienced disease progression after receiving either sorafenib or sunitinib.
Condition | Intervention | Phase |
---|---|---|
Renal Cell Carcinoma |
Drug: Perifosine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma |
Estimated Enrollment: | 48 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
This is a single-arm phase II trial assessing the antitumor activity as measured by progression free survival of perifosine in patients with metastatic RCC who have progressed on sorafenib or sunitinib. A total of 48 patients will be enrolled in the trial. All subjects will have histologically confirmed metastatic RCC with predominantly clear cell features (≤ 50% other histologic features). Patients who have been taken off sorafenib or sunitinib may only have been off therapy for less than three months prior to study enrollment. Patients who remain on sorafenib or sunitinib may continue on drug at their current dose until two weeks prior to the initiation of perifosine therapy.
The study consists of three periods: pre-treatment/screening, treatment, and follow-up. Day 1 will be defined as the first day of perifosine therapy. Patients will remain in the treatment phase until progression or toxicity.
Patients will be seen by an MD every 3 weeks with 6 weeks defining one cycle of therapy. Tumor evaluations will occur every 6 weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have the following laboratory values
Exclusion Criteria:
Patients with clinically significant cardiovascular disease
United States, California | |
AOI Pharmaceuticals Investigative Site | |
Duarte, California, United States, 91010 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, Pennsylvania | |
AOI Pharmaceuticals Investigative Site | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Tennessee | |
AOI Pharmaceuticals Investigative Site | |
Nashville, Tennessee, United States, 37232 |
Principal Investigator: | Daniel Cho, MD | Dana-Farber Cancer Institute |
Responsible Party: | AOI Pharma, Inc. ( AOI Pharma, Inc. ) |
Study ID Numbers: | Perifosne 228 |
Study First Received: | March 15, 2007 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00448721 History of Changes |
Health Authority: | United States: Food and Drug Administration |
renal cell carcinoma tyrosine kinase inhibitor failure |
Urinary Tract Neoplasm Kidney Cancer Tyrosine Urogenital Neoplasms Urologic Neoplasms Carcinoma Renal Cancer |
Urologic Diseases Kidney Neoplasms Carcinoma, Renal Cell Kidney Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Urologic Diseases Kidney Neoplasms Carcinoma, Renal Cell |
Urogenital Neoplasms Kidney Diseases Urologic Neoplasms Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |